Business Description
Alvotech
NAICS : 325412
SIC : 2834
ISIN : LU2458332611
Total Employee Number:
1,460Description
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.04 | |||||
Equity-to-Asset | -0.2 | |||||
Debt-to-Equity | -5.16 | |||||
Debt-to-EBITDA | 6.45 | |||||
Interest Coverage | 0.54 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.99 | |||||
Beneish M-Score | -3.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 68.6 | |||||
3-Year EPS without NRI Growth Rate | 40.1 | |||||
3-Year FCF Growth Rate | 35 | |||||
3-Year Book Growth Rate | 26.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 135.97 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.32 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.99 | |||||
9-Day RSI | 44.9 | |||||
14-Day RSI | 46.19 | |||||
3-1 Month Momentum % | 22.93 | |||||
6-1 Month Momentum % | -10.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.76 | |||||
Quick Ratio | 0.88 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 321.91 | |||||
Days Sales Outstanding | 59.02 | |||||
Days Payable | 157.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | -15.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.35 | |||||
Operating Margin % | 13.82 | |||||
Net Margin % | -14.43 | |||||
EBITDA Margin % | 40.39 | |||||
FCF Margin % | -43.13 | |||||
OCF Margin % | -21.84 | |||||
ROA % | -5.8 | |||||
3-Year ROIIC % | 80.19 | |||||
ROC (Joel Greenblatt) % | 33.3 | |||||
ROCE % | 16.79 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 50.37 | |||||
PS Ratio | 1.75 | |||||
EV-to-EBIT | 13.49 | |||||
EV-to-Forward-EBIT | 7.49 | |||||
EV-to-EBITDA | 11.11 | |||||
EV-to-Forward-EBITDA | 6.94 | |||||
EV-to-Revenue | 4.49 | |||||
EV-to-Forward-Revenue | 2.66 | |||||
EV-to-FCF | -10.36 | |||||
Price-to-GF-Value | 0.18 | |||||
Earnings Yield (Greenblatt) % | 7.41 | |||||
FCF Yield % | -21.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alvotech Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 480.934 | ||
| EPS (TTM) (€) | -0.247 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 46.19 | ||
| 14-Day ATR (€) | 0.148769 | ||
| 20-Day SMA (€) | 3.1365 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.62 - 4.85 | ||
| Shares Outstanding (Mil) | 338.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alvotech Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alvotech Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:00 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-11 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 08:00 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 35 days | ||
| UBS Virtual Generics and Biosimilars Day | 2026-06-10 10:30 | 3.69 (+0.00%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 08:40 | 3.18 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 09:20 | 2.64 (+0.00%) | ||
| General meeting for 2026 | 2026-06-03 | 2.84 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 3.02 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 3.17 (+3.93%) |
Show
Entries
Alvotech Frequently Asked Questions
What is Alvotech(HAM:Z45)'s stock price today?
The current price of HAM:Z45 is €2.95. The 52 week high of HAM:Z45 is €4.85 and 52 week low is €2.62.
When is next earnings date of Alvotech(HAM:Z45)?
The next earnings date of Alvotech(HAM:Z45) is 2026-08-19.
Does Alvotech(HAM:Z45) pay dividends? If so, how much?
Alvotech(HAM:Z45) does not pay dividend.
Press Release
Articles on Alvotech
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers